semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acromegaly Male and female patients (> 18 years) with prior surgery of micro or macroadenoma of the pituitary At least 6 months chronic treatment with 30mg octreotide (long acting release) Partial responsiveness, which is defined as follows: at any one point within the 6 months monotherapy with 30mg/month octreotide (long acting release) the patient must have experienced a decrease in GH and IGF-1 of at least 25% as compared to pre-monotherapy values (= baseline). Note: For efficacy analysis GH and IGF-1-values measured in the central laboratory at visit 1 (=study baseline) will be used Lack of suppression of GH nadir to < 1.0 µg/L, after oral administration of 75 g of glucose (OGTT) and IGF-I levels at least 10% above the normal value ± 2 SD (adjusted for age and gender; Brabant 2003) must be proven within 4 weeks prior to visit 1. However, if acromegaly symptoms are inadequately controlled as defined in the acromegaly comorbidities and symptom evaluation (as judged by the investigator), an abnormal GH or IGF-1-value as defined above is sufficient Patient's written informed consent  Requires surgery for recent significant deterioration in visual fields or other neurological signs, which are related to the pituitary tumor mass Radiotherapy planned or radiotherapy for acromegaly within the last 2 years Symptomatic cholelithiasis that is clinically relevant Receiving treatment with dopamine agonists within the last 6 months or prior treatment with GH-receptor-antagonists Patients with renal insufficiency, Raynaud-Syndrome or gastrointestinal ulcer/ bleeding cannot be included in the study or psychose in anamnesis. Other protocol-defined inclusion/
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 0.0-0.096,  Vitamin D Deficiency Healthy singleton term born infants of appropriate size for gestational age (AGA) according to the Centers for Disease Control growth charts based on weight at birth between the 5th and 95th percentiles for sex; and born to healthy breastfeeding women. This allows us to assess growth and bone mineral accretion without bias of intrauterine growth restriction  Infants of mothers with history of gestational diabetes or hypertension in pregnancy; chronic alcohol use; malabsorption syndromes due to malabsorption of vitamin D (celiac disease, Crohn's etc.); and multiple births Should any be identified after recruitment, the infant will be excluded from the main analyzes, but followed in a separate arm as intent-to-treat
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Acromegaly The patient must have had documentation supporting the diagnosis of acromegaly, including elevated GH and/or IGF-1 levels The patient is treated with pegvisomant, because of IGF-1 level remaining above ULN when treated with somatostatin analogue, on a daily basis for at least 3 months and has normal (age and sex adjusted) IGF-1 level, or IGF-1 level above the upper limit of normal (ULN) after treatment with pegvisomant 30 mg per day, OR the patient is treated with lanreotide Autogel or octreotide LAR for at least 6 months including 3 months at the highest marketed dose and has a serum IGF-1 level above ULN, 28 days after the last injection At the end of the run-in period, The patient has a serum IGF-1 level above 1.2 x ULN, or a serum IGF-1 level between ULN and 1.2 x ULN and a serum GH nadir > 1 µg/L (assessed by an OGTT), 28 days after the 3rd injection of lanreotide Autogel 120 mg OR the patient is diabetic and has a serum IGF-1 level above 1.2 ULN, 28 days after the 3rd injection of lanreotide Autogel 120 mg  The patient has undergone pituitary surgery or radiotherapy within 6 months prior to study entry, or it is anticipated that it will be done during the study The patient has already been treated with a somatostatin analogue associated with a GH antagonist The patient has received dopamine agonist within 6 weeks prior to the study entry The patient has abnormal hepatic function at study entry (defined as AST, ALT, GGT, alkaline phosphatase, prothrombin time or total bilirubin above 2 ULN) The patient is at risk of pregnancy or is lactating
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Carcinoid Tumor Acromegaly for patients with acromegaly Male or female patients between 18 and 80 years Patients with acromegaly due to a pituitary adenoma with elevated GH and IGF-1 concentrations  for patients with acromegaly Patients with compression of the optic chiasm causing any visual field defect Specific apply for patients who have received certain types of therapies such as radiotherapies, surgeries, chemo or immunotherapies in the months prior to study start Female patients who are pregnant or lactating for patients with carcinoid disease Male or female patients aged ≥18 years Patients with histologically confirmed, metastatic carcinoid tumors of the digestive system Patients with elevation of chromogranin-A (CgA) and/or serotonin Patients who are not adequately controlled by somatostatin analogues for patients with carcinoid disease
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acromegaly The subject must give signed informed consent before any study-related activities The partner, if applicable, must give signed informed consent before administration of Somatuline Autogel The subject must be able to understand the protocol requirements The subject must have a clinical diagnosis of acromegaly due to pituitary tumor The subject must be treated with a long-acting somatostatin analogue with or without a dopamine agonist and have been on the current medical regimen for at least 3 months prior to screening and have IGF-1 levels no higher than 10% above the upper limit of the normal range for age and gender at the screening visit or be somatostatin analogue naïve (if the subject is treated with a dopamine agonist he/she must have been on the current dose for at least 3 months prior to screening) Subjects who are treated with a dopamine agonist have to stay on their current dose for the duration of the study Switch subjects must have had their last pre-study routine clinical treatment with Sandostatin LAR between 28 and 35 days before Visit 2 (enrollment) The subject must be able to store the study medication in a refrigerator in his/her own or his/her partner's home The subject must be ≥18 years of age Female subjects of childbearing potential must use adequate contraception  The subject has had pituitary surgery (adenomectomy) within 3 months prior to screening The subject has received pituitary radiotherapy within 3 years prior to screening The subject has received a GH receptor antagonist within 6 months prior to screening The subject is currently on a higher dose of Sandostatin LAR than 30mg q28d The subject is pregnant or breastfeeding The subject has clinically significant renal or hepatic abnormalities The subject has a symptomatic, untreated biliary lithiasis The subject has uncontrolled diabetes or thyroid disease The subject has a known hypersensitivity to any of the test materials or related compounds The subject is unable or unwilling to comply with the protocol
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acromegaly patients with newly diagnosed acromegaly age above 18 years no previous treatments for acromegaly  primary surgery concomitant hyperprolactinemia if requiring combined treatment with dopamine-agonist primary treatment with lanreotide treatment duration less than 24 months
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 6.0-999.0,  Acromegaly Gigantism Familial Isolated Pituitary Adenoma FIPA Pituitary Adenoma Predisposition PAP Familial acromegaly or other type of pituitary tumour OR Early onset acromegaly or Sporadic pituitary tumour  Do not consent
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Acromegaly Growth Hormone Deficiency for acromegaly Clinical and biochemical diagnosis of acromegaly. Thyroid and glucocorticoid replacement if necessary stable for at least 4 weeks before the study. Gonadotrophin status will be recorded and whenever possible patients will be studied in the same status Males and females aged 18-70 years willing to give informed consent At least 6 months after the onset of symptoms of acromegaly and on stable medication for heart failure treatment (if any) for at least 4 weeks prior to into the study Systolic blood pressure < 180 mmHg, diastolic blood pressure < 110 mmHg. for GHD Clinical and biochemical diagnosis of GHD. All hormones replaced (if clinically necessary) except GH. Thyroid and glucocorticoid replacement if necessary stable for at least 4 weeks before the study. Gonadotrophin status will be recorded and whenever possible patients will be studied in the same status Males and females aged 18-70 years willing to give informed consent At least 6 months after the onset of symptoms of acromegaly and on stable medication for heart failure treatment (if any) for at least 4 weeks prior to into the study Systolic blood pressure < 180 mmHg, diastolic blood pressure < 110 mmHg  for acromegaly Change in medication in the preceding 4 weeks Patients on subcutaneous insulin therapy Hyperthyroidism Not being in sinus rhythm Unstable angina pectoris and decompensated heart failure (define as NYHA 3-4) Clinically significant valvular disease, clinically significant chronic obstructive pulmonary disease History of myocardial infarction or stroke within the last 6 months, major cardiac surgery within the last 6 months Significant history of drug or alcohol abuse or unable to give informed consent
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Severe Adult Growth Hormone Deficiency Over 18 years of age Confirmed severe AGHD GH response <9 mU/l (preferably <4) to insulin-induced hypoglycaemia or glucagon stimulation test plus (These tests will have taken place as part of routine management) Full, stable pituitary replacement therapy Willing to provide informed consent  Unwilling to provide written consent Current GH therapy Pharmacological doses of glucocorticoids Any acute illness
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Acromegaly Patient on treatment with octreotide LAR 20 mg administered every 28 days for at least 3 months prior to visit 1 Patient must have serum GH level ≤ 2.5 ng/mL and serum IGF-1 ≤ 1.3 ULN, 28 days after their last injection of octreotide LAR 20 mg at visit 1 Patients must have serum GH level > 2.5 ng/mL AND serum IGF-1 level > 1.3 ULN, 6 or 8 weeks after their last injection of octreotide LAR 20 mg  The patient has received pituitary radiation therapy of any kind at any time prior to visit 1 The patient has received pituitary surgery within 3 months prior to visit 1 The patient's serum creatinine is higher than 150 µmol/l
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Acromegaly GH nadir during a standard 75 g OGTT >= 5.0 mmol/L Pituitary tumor by MRI-scan  Immediate surgery indicated by usual clinical criteria Pregnant Known adverse effects of octreotide Unfit for participation by any other reason
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-96.0,  Obesity Bariatric Surgery Gastric Bypass Weight Loss Hyperglycemia Subjects must initially qualify for bariatric surgery according to current NIH guidelines, which require the presence of either morbid obesity alone (BMI greater than 40 kg/m(2)) or a BMI greater than 35 kg/m(2) along with at least 2 other co-morbidities Patients with conditions such as sleep apnea, mild steatohepatitis, GERD, asthma (not requiring oral steroids) and osteoarthritis can be considered for participation Subject with undiagnosed diabetes (2-h glucose greater than 200 mg/dl during initial screening OGTT) will be included in the IGR group ONLY IF BOTH fasting plasma glucose is less than 126 mg/dl and HbA1c is less than 7 percent, suggesting early T2DM Subjects must be at least 18 years of age and less than 150 kg body weight Males and females of all ethnic minorities will be included  Because of the indications for bariatric surgery, many potential subjects will have underlying co-morbidities associated with obesity. For this protocol, subjects will be excluded for the following Current smoking Previously diagnosed diabetes Other endocrine disorders, such as Cushing's disease, pituitary disorders, and thyroid disease Significant hepatic or renal disease (ALT and AST greater than 3-fold above upper limit of normal range, cirrhosis, active hepatitis B or C, serum creatinine greater than 1.5 mg/dl or presence of protein in urine dipstick) Active tuberculosis (self-report) Major pulmonary disorders including physician diagnosed chronic obstructive pulmonary diseases other than obstructive sleep apnea Cardiovascular diseases, including coronary heart disease, heart failure, arrhythmias, and peripheral artery disease Hypertension (according to the World Health Organization diagnostic criteria), treated or uncontrolled Gastrointestinal disease, including inflammatory bowel diseases (e.g. Crohn's disease and ulcerative colitis), malabsorption syndromes (e.g. celiac disease), gastric ulcer (active)
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acromegaly Diagnosis of active acromegaly based on evidence of a pituitary tumor Historical serum insulin-like growth factor (IGF)-I levels or a lack of suppression of growth hormone (GH) < 1 ng/mL during an oral glucose tolerance test Previous treatment with a stable dose of octreotide LAR for at least 3 months No previous treatment with a stable dose of octreotide LAR for at least 3 months after receiving 3 months of octreotide LAR during a run-in phase prior to any other study-related activity  Uncontrolled diabetes mellitus Pregnant or breast feeding Current gallstones History of hepatic disease, except patients with < 3 X ULN LFTs indicative of hepatic steatosis Past or current history of cancer, except for basal cell carcinoma or in situ cancer of the cervix History of glucocorticoid therapy within the past 6 months, current treatment with any chemotherapeutic agents or exogenous GH therapy History of investigational drugs administered or received within 30 days of study entry Known hypersensitivity to octreotide LAR Any other concomitant illnesses or therapy that would interfere with evaluation of efficacy or safety or increase the risk for study interruption or discontinuation in the opinion of the investigator or sponsor
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Obesity Growth Hormone for Obesity Body mass index (BMI) greater than or equal to 30 kg/m2 Abdominal obesity, defined as waist circumference greater than or equal to 102 cm in men and greater than or equal to 88 cm in women for Lean Controls BMI less than 25 kg/m2 Waist circumference less than 102 cm in men and less than 88 cm in women  for both groups Obesity due to known secondary causes Taking any weight lowering drugs Previous bariatric surgery Use of the following compounds within the 3 months prior to study entry: estrogen, progesterone, GH, GHRH, glucocorticoids, megesterol acetate, antidiabetic agents, oral contraceptive pills, or any other hormone or drug known to affect GH levels Change in lipid lowering or antihypertensive regimen within 3 months prior to study entry Use of testosterone or hormone replacement therapy Previously known diabetes mellitus or other severe chronic illness Hemoglobin less than 11.0 g/dL, creatinine greater than 1.5 mg/dL, or serum glutamic oxaloacetic transaminase (SGOT) greater than 2.5 times the upper limit of normal Follicle stimulating hormone (FSH) greater than 20 IU/L in women
Patient description: The patient is a 41-year-old man and a known case of Acromegaly who underwent transsphenoidal surgery 4 months ago. He came to the clinic for the follow up lab studies after his primary resection surgery. His lab study shows the IGF-1 level of 4.5 ULN adjusted by sex and age. His random GH level is 4 ug/L. The recent brain MRI confirmed the residual pituitary tumor. His past medical history is only significant for acromegaly due to pituitary adenoma and the recent surgery. After his surgery he takes only vitamin D and multivitamins.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pituitary Tumor patients with confirmed pituitary disease  patients who do not have confirmed pituitary disease